Entering text into the input field will update the search result below

Arena Pharmaceuticals Announces Positive Phase 2 Results in PAH

Jul. 11, 2017 2:10 PM ETPfizer Inc. (PFE)OREX, VVUS22 Comments


  • Ralinepag shows remarkable improvement in patients with pulmonary arterial hypertension.
  • Positive results in the PAH trial was a much needed change after the company's first FDA approved product didn't sell well.
  • Cash is only expected to last for the next 12 months.

Monday, Arena Pharmaceuticals (ARNA) announced positive phase 2 results in patients with pulmonary arterial hypertension. The stock shot up as high as 41% in after-hours trade on the news to $25.99 per share. These results paint a new picture for Arena who has suffered over the last few years with an obesity drug known as Belviq.

Phase 2 Data

The phase 2 trial recruited a total of 61 patients with pulmonary arterial hypertension -- PAH. Patients in the study either took Ralinepag or a placebo. The trial met on the primary endpoint of the study in that the drug demonstrated a statistically significant absolute change in baseline in pulmonary vascular resistance -- PVR. Patients treated with ralinepag showed a 29.8% improvement in PVR compared to placebo with a p-value of p=0.03. That means that the primary endpoint reached statistical significance. In addition, there was a 20.1% improvement in patients treated with ralinepag compared to baseline. Arena plans to present the full positive data at a future medical conference. What is even better is that this data gives the company the backing to move to a phase 3 clinical trial. The Chief Scientific Officer of Arena, Preston Klassen, M.D. had this to say in a quote:

"It is exciting to see the positive nonclinical pharmacological profile translating into potentially the first oral prostacyclin therapy that may approach consistent therapeutic levels without the complexity of parenteral (IV) therapy. These data give us confidence to move expeditiously toward a Phase 3 clinical program."

What is being described above is that the oral drug from Arena Ralinepag might be close to achieving the same therapeutic effect as those drugs that are given intravenously. An oral treatment option for these patients would be a lot more ideal. PAH is a life threatening disease because there is a

This article was written by

Terry Chrisomalis profile picture
Actionable ideas on small-large cap biotech stocks through deep analysis.

I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha.

You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (62.5K) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.